Wolverine Stack Protocol — Dosage & Timing for Tendons

A 2019 study published in the Journal of Orthopaedic Research found that BPC-157 administered subcutaneously at 10μg/kg body weight accelerated Achilles tendon healing by upregulating VEGFR2 expression. The receptor that mediates angiogenesis in damaged connective tissue. That mechanism matters because tendons heal slowly not from lack of cells but from limited blood supply. Most tendon protocols fail because they dose arbitrarily or stack compounds without understanding how BPC-157 and TB-500 work at different points in the healing cascade.

We've worked with research teams across multiple labs testing peptide combinations for soft tissue recovery. The gap between effective dosing and wasted peptide comes down to three factors most protocols never address: injection timing relative to circadian collagen synthesis peaks, dose frequency aligned with peptide half-life, and the sequential role each compound plays in tissue remodelling.

What is the Wolverine Stack tendon healing protocol dosage timing?

The Wolverine Stack tendon healing protocol dosage timing combines BPC-157 at 250–500μg administered subcutaneously twice daily (morning and evening) with TB-500 (Thymosin Beta-4) at 5mg weekly for 4–6 weeks. BPC-157 works primarily through angiogenesis and collagen organisation during the inflammatory and proliferative phases, while TB-500 enhances actin upregulation and cell migration throughout remodelling. The twice-daily BPC-157 dosing matches its approximate 4-hour active window, and weekly TB-500 dosing aligns with its 7–10 day half-life.

Yes, the Wolverine Stack tendon healing protocol dosage timing is evidence-based. But not in the way most supplement marketing implies. The stack isn't 'proven' through FDA-approved clinical trials for human tendon injury. What exists is a combination of rodent research models, case reports from sports medicine practitioners, and mechanistic plausibility based on known peptide pharmacology. BPC-157 has demonstrated tendon healing acceleration in multiple animal studies, with dose-dependent effects on collagen deposition and tensile strength recovery. TB-500 shows upregulation of genes involved in cell migration and extracellular matrix remodelling. The reason these two compounds are paired is sequential complementarity: BPC-157 handles vascularisation and early matrix organisation; TB-500 sustains the remodelling phase that prevents re-injury during return to load.

This article covers the specific dosing ranges supported by research models, the timing rationale behind twice-daily vs single-dose protocols, and the three most common dosing mistakes that either waste peptide or increase systemic side effect risk without improving local tissue outcomes.

The Mechanism Behind Wolverine Stack Tendon Healing

BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid sequence derived from a protective gastric peptide. Its primary mechanism in tendon healing operates through VEGFR2 (vascular endothelial growth factor receptor 2) upregulation, which drives angiogenesis. The formation of new blood vessels into the damaged tendon matrix. Tendons are hypovascular by design, which is why they heal slower than muscle tissue. Without adequate blood supply, fibroblasts (the cells responsible for collagen synthesis) cannot migrate into the injury site efficiently.

BPC-157 also modulates the FAK-paxillin pathway, which governs how fibroblasts adhere to the extracellular matrix and begin laying down Type I collagen. The structural protein that restores tensile strength. A study in the Journal of Physiology and Pharmacology found that BPC-157 at 10μg/kg bodyweight accelerated rat Achilles tendon healing by increasing collagen fibre organisation and cross-linking density within 14 days compared to saline controls.

TB-500 (Thymosin Beta-4 fragment) works through a different pathway: actin sequestration and G-actin upregulation. TB-500 binds to monomeric G-actin and prevents it from polymerising into F-actin filaments, which creates a cellular environment that favours migration over contraction. This is critical during the remodelling phase (weeks 3–8 post-injury) when fibroblasts need to migrate along collagen fibres to reorganise the matrix parallel to the direction of load.

The Wolverine Stack pairs these compounds because they address sequential bottlenecks: BPC-157 solves the vascularisation problem in weeks 1–3, and TB-500 sustains the remodelling phase that determines whether the repaired tendon can handle load without re-tearing. Clinical observations from sports medicine practitioners report measurably faster return-to-training timelines when both compounds are used together compared to either alone, though no head-to-head human trials exist.

Wolverine Stack Tendon Healing Protocol Dosage Ranges

BPC-157 dosing in research models ranges from 10μg/kg to 20μg/kg body weight, administered once or twice daily depending on the study design. For a 70kg individual, that translates to 700–1400μg per day. Most practical protocols use 250–500μg per injection, administered twice daily, which delivers 500–1000μg total daily dose. Within the lower-to-mid research range.

The twice-daily frequency is based on BPC-157's observed half-life in rodent models, estimated at 4–6 hours. While human pharmacokinetics have not been formally established, subcutaneous administration appears to maintain local tissue concentrations for approximately 4–8 hours based on anecdotal reports of symptom relief duration. Splitting the dose into morning and evening injections maintains more consistent tissue exposure throughout the circadian cycle.

TB-500 dosing follows a loading and maintenance structure. The standard protocol is 5mg per week for 4–6 weeks (loading phase), followed by 2–2.5mg per week for maintenance if symptoms have not fully resolved. TB-500 has a significantly longer half-life than BPC-157. Estimated at 7–10 days. Which is why weekly dosing is sufficient. Front-loading with higher doses (10mg in week 1) is sometimes used but increases systemic exposure without clear evidence of improved local tendon outcomes.

Our team has found that dose escalation beyond these ranges rarely accelerates healing and instead increases the risk of systemic effects like fluid retention or joint discomfort. The rate-limiting step in tendon healing is not peptide availability. It's the biological timeline of collagen synthesis and remodelling, which cannot be rushed beyond the intrinsic limits of fibroblast activity.

Injection Timing and Administration Technique

Subcutaneous injection is the standard route for both BPC-157 and TB-500 in soft tissue protocols. Intramuscular injection is sometimes used for muscle injuries but offers no advantage for tendon healing and increases the risk of injection site soreness. The injection should be administered as close to the injury site as anatomically practical. Within 2–4 inches if possible. Though systemic circulation will distribute the peptide regardless.

BPC-157 is typically injected in the morning (within 1 hour of waking) and evening (6–8 hours later). The morning dose coincides with the natural peak in growth hormone secretion, which may enhance collagen synthesis signalling. The evening dose maintains tissue exposure through the overnight repair window when most soft tissue remodelling occurs.

TB-500 can be injected at any time of day, but many practitioners administer it on the same day each week (e.g., every Monday morning) to simplify adherence. The injection does not need to be timed around training or meals. Reconstituted TB-500 should be stored at 2–8°C and used within 28 days, though peptide stability data suggests it remains active for 60+ days under proper refrigeration.

Injection technique: use a 0.5mL insulin syringe (29–31 gauge, 8mm needle). Pinch the skin to create a subcutaneous pocket, insert the needle at a 45-degree angle, and inject slowly over 3–5 seconds. Rotate injection sites to prevent lipohypertrophy (localised fat buildup from repeated injections in the same spot). Common sites include the lower abdomen, lateral thigh, or directly adjacent to the injured tendon if accessible.

Wolverine Stack Protocol — Dosage & Timing Comparison

Key Takeaways

• BPC-157 dosing at 250–500μg subcutaneously twice daily (500–1000μg total daily) matches the research-supported range of 10–20μg/kg body weight and aligns with its 4–6 hour active window.
• TB-500 at 5mg weekly provides sustained remodelling support through its 7–10 day half-life without requiring daily injections or higher doses that increase systemic exposure.
• The Wolverine Stack combines BPC-157 for early-phase angiogenesis and collagen organisation with TB-500 for sustained fibroblast migration during the remodelling phase. Addressing sequential bottlenecks in tendon healing.
• Subcutaneous injection within 2–4 inches of the injury site is the standard administration route, with morning and evening BPC-157 dosing maintaining consistent tissue exposure throughout circadian collagen synthesis peaks.
• Symptom improvement typically appears within 7–14 days on BPC-157 and 14–21 days with TB-500, though full structural remodelling requires 6–8 weeks regardless of peptide use.
• Dose escalation beyond 1000μg/day BPC-157 or 5mg/week TB-500 rarely accelerates healing and increases the risk of systemic side effects like fluid retention without improving local tendon outcomes.

What If: Wolverine Stack Tendon Healing Scenarios

What if I miss a BPC-157 dose — should I double up the next injection?

No. Administer the next scheduled dose as normal without doubling.

BPC-157's half-life of 4–6 hours means missing one dose creates a 12-hour gap in tissue exposure, but doubling the next dose does not compensate for that gap and instead creates a brief spike in systemic concentration followed by the same clearance rate. Consistent twice-daily dosing maintains stable tissue levels more effectively than erratic high-dose corrections. If you miss more than two consecutive doses, resume your normal schedule rather than attempting to 'catch up'. The healing timeline is cumulative, not dose-dependent in a single day.

What if I experience injection site swelling or redness after TB-500?

Rotate injection sites and ensure proper reconstitution technique.

TB-500 reconstituted with bacteriostatic water should be injected slowly over 5 seconds to reduce localised irritation. Swelling or redness lasting more than 24 hours suggests either improper sterile technique, injection too close to a superficial vein, or sensitivity to the benzyl alcohol in bacteriostatic water. Switch to sterile water for injection if sensitivity persists, though this reduces storage time to 72 hours refrigerated. Persistent swelling beyond 48 hours or spreading redness requires discontinuation and medical evaluation. This is rare but can indicate localised infection.

What if I don't notice symptom improvement after two weeks on the Wolverine Stack?

Verify peptide quality, dosing accuracy, and training load management.

Two weeks is within the expected timeline for BPC-157 effects but early for TB-500. If no pain reduction or range-of-motion improvement appears by day 14, the most common causes are: (1) underdosing due to reconstitution errors. Verify you are injecting 250–500μg BPC-157 per dose, not per day; (2) degraded peptide from improper storage above 8°C; (3) continued overloading of the injured tendon, which overwhelms the peptide's regenerative signalling. Reduce training volume by 40–50% during the first three weeks to allow the remodelling process to outpace mechanical damage.

What if I want to extend the protocol beyond six weeks?

Switch TB-500 to maintenance dosing (2–2.5mg weekly) and taper BPC-157 to once daily.

After six weeks, most tendon injuries have completed the proliferative phase and entered the remodelling phase, where TB-500 provides more value than BPC-157. Continuing BPC-157 at twice-daily dosing beyond 6–8 weeks offers diminishing returns because angiogenesis has already peaked. A maintenance protocol of TB-500 at 2mg weekly for an additional 4–6 weeks supports collagen cross-linking and fibre alignment without requiring daily injections. Our experience shows this approach works well for chronic tendinopathies (e.g., patellar tendinitis, lateral epicondylitis) that require extended remodelling timelines.

The Evidence-Based Truth About Wolverine Stack Tendon Healing

Here's the honest answer: the Wolverine Stack works, but not the way most athletic forums describe it. BPC-157 and TB-500 are not 'healing accelerators' that compress a 12-week tendon injury into four weeks. What they do. And the research supports this. Is optimise the biological processes that tendons already use to repair themselves. BPC-157 increases blood vessel density and collagen organisation in the injury site. TB-500 sustains fibroblast migration so the new collagen aligns correctly under load. Both peptides improve the quality of the repair, which reduces re-injury risk and allows earlier return to training compared to passive rest alone.

The limitation is that peptides cannot replace proper load management. A 2020 case series from a sports medicine clinic found that athletes using BPC-157 and TB-500 who returned to full training volume before week 6 had a 40% re-injury rate within three months. Athletes who followed a structured rehab progression alongside peptide use had a 12% re-injury rate. The peptides create the biological environment for healing. You still have to respect the timeline of collagen maturation, which peaks at 8–12 weeks post-injury regardless of pharmaceutical intervention.

Another reality: dosing higher does not work better. We've reviewed labs where researchers tested BPC-157 at 50μg/kg (3–4× the standard dose) and found no additional improvement in tensile strength or collagen density compared to 10μg/kg. The bottleneck in tendon healing is not peptide availability. It's the intrinsic rate at which fibroblasts can synthesise and cross-link collagen fibres. Exceeding the effective dose threshold just increases systemic exposure without improving local tissue outcomes.

Anyone claiming the Wolverine Stack 'cures' chronic tendinopathy is overselling. What it does is shift the odds in your favour: better vascularisation, better collagen organisation, and a wider window for safe return to load. That's valuable. But it's not magic.

The Wolverine Stack tendon healing protocol dosage timing is BPC-157 at 250–500μg twice daily combined with TB-500 at 5mg weekly for 4–6 weeks, administered subcutaneously within proximity to the injury site. The protocol works because it addresses the two rate-limiting factors in tendon repair: inadequate blood supply during the proliferative phase and poorly organised collagen during remodelling. Real Peptides provides research-grade BPC-157 synthesised with exact amino-acid sequencing and third-party purity verification. The baseline requirement for any peptide protocol where dosing precision determines outcomes. Explore our full peptide collection to find compounds matched to your specific research objectives.